Leading Justice
  • HOME
  • Current Campaigns
  • Medical Record Retrieval
  • Contact Us
Home > Elmiron
Prev
  / 
Next

Elmiron

Leading Justice is offering limited Elmiron advertising and virtual secretarial services for mass tort law firms pursuing an increased case docket of Elmiron maculopathy claims. With more than 15 years of experience helping consumers harmed by Big Pharma and the staying power of an honest, 100% fraudulent-free business history, Leading Justice has the transparency in advertising to be your partner in building a large Elmiron eye damage docket. Leading Justice will create and place Elmiron injury media for your buy and screen all Elmiron vision loss-related contacts according to your qualifying case criteria. We will single sign the client’s claim to your retainer/medical release using the most rigorous security industry certification standards and send the signed Elmiron maculopathy claim to your intake team for the final screen and medical record retrieval.

If your firm is interested in pursuing Elmiron-associated retinal maculopathy, vision loss or blindness claims, Leading Justice can build your docket via our effective advertising and virtual secretarial services. Law firms partnered with Leading Justice know they are working with an honest, transparent advertising shop that will build their Elmiron maculopathy docket with marketing best practices and bar opinions in mind.

Name and Contact Info Confirmed
Confirmed Exposure to Elmiron
Vision Loss Confirmed
Seeking A Lawyer Confirmed

Call Us Now

Elmiron Contacts

(800) 426-1207

Tags: blindness, elmiron, interstitial cystitis, maculopathy, painful bladder syndrome, pentosan polysulfate, pigmentary maculopathy, retinal maculopathy, vision loss.
share on
Facebook
pin this item
on Pinterest
share it on
Twitter
Send to a
friend
  • Description
  • Product Inquiry

Product Description

Leading Justice is a full-service marketing company working with law firms on a cash-buy basis to sign up fully qualified, fraud-free pentosan polysulfate-related maculopathy cases. Here at Leading Justice, we can customize your firm’s Elmiron advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Elmiron maculopathy advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that doesn’t qualify for the target campaign is evaluated to determine whether it qualifies for another type of claim. By using advanced approaches to target contacts specifically related to Elmiron and side effects like pigmentary maculopathy, eye damage, vision loss and blindness, Leading Justice will increase your firm’s Elmiron caseload. If you are interested in helping victims of Elmiron side effects, our direct advertising strategies and extensive consumer reach at Leading Justice give you the competitive edge and confidence you need to allocate your full budget, knowing that your money is being spent in the best way possible.

Each law firm we work with at Leading Justice plays an important role in determining how we categorize claims as qualified or not. And while our experience working with plaintiff law firms allows us to recognize a great case when we see one, we will tailor our Elmiron vision loss intake specifications to the exact criteria you are seeking. So, if your firm has specific Elmiron qualifying case criteria you want us to use, we can train our intake specialists to apply the criteria to each phone call and email they receive. By eliminating the middle man, Leading Justice offers clients an opportunity for internal cash buys of Elmiron maculopathy data with zero chance of fraud.

Elmiron Maculopathy Litigation

Since 1996, the bladder drug Elmiron (pentosan polysulfate or PPS) has been marketed in the United States as a safe and effective treatment for interstitial cystitis (IC), a chronic condition that is part of a spectrum of diseases known collectively as painful bladder syndrome. Many of these patients experienced symptoms like vision loss, blurred vision, difficulty reading and vision distortion during or after Elmiron treatment and were diagnosed with macular degeneration, Stargardt disease or another eye disease, only to find out now that their irreversible vision problems may have been caused by Elmiron. Because Elmiron is currently the only FDA-approved oral medication for interstitial cystitis, most IC patients take Elmiron for years, if not decades. And because the vision problems linked to Elmiron are commonly misdiagnosed as macular degeneration, patients suffering from pentosan polysulfate-related maculopathy may continue taking Elmiron, unaware that the drug may be what is causing their problems.

The first warnings about the potential link between Elmiron and a unique form of progressive eye disease, typically diagnosed by ophthalmologists as age-related macular degeneration, pattern dystrophy or Stargardt disease, came in May 2018. In a study published in the journal Ophthalmology, researchers from the Emory Eye Institute in Atlanta, Georgia highlighted six patients experiencing a “unique pigmentary maculopathy,” which the researchers linked to “chronic exposure to pentosan polysulfate sodium (PPS).” There are now more than a dozen reports and papers detailing cases where interstitial cystitis patients taking Elmiron have experienced retinal maculopathy or pigmentary maculopathy possibly leading to irreversible vision loss and eye dysfunction. For more than 20 years, Elmiron has been used by hundreds of thousands of patients with interstitial cystitis or painful bladder syndrome, and many of these patients are now pursuing legal claims against drug maker Janssen Pharmaceuticals. The Elmiron lawsuits accuse the company of failing to properly research the long-term health effects of Elmiron and failing to issue adequate warnings to patients in the United States about the potential for Elmiron to cause permanent vision loss or blindness.

* Insert the name
* Insert a valid email
* Insert a subject
* Insert a message

Copyright 2015-2021 Citizen Ad Network, LLC